Celecoxib for the prevention of colorectal adenomatous polyps.

By N. Arber, C. Eagle, J. Spicak, I. Rácz, P. Dítě, J. Hajer, M. Zavoral, M. Lechuga, P. Gerletti, Jie Tang and 8 more. New England Journal of Medicine, 2006

911 citations recorded by the source corpus.

Subfields: Oncology, Pharmacology, Psychiatry and Mental health

View Paper: https://www.semanticscholar.org/paper/3e9c8e58c35f6132bdd678f0bef85fa8ce58cf3c

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

In Pharmacology

B. Sasikumar

Citations in the corpus

Guidelines for colonoscopy surveillance after screening and polypectomy: a consensus update by the US Multi-Society Task Force on Colorectal Cancer. (2012, neutral): “11,54–57 We believe there is insufﬁcient evidence to recommend any change in surveillance intervals in patients who are taking these medications.”
Inflammation: gearing the journey to cancer. (2008, background): “According to a randomized, placebocontrolled, double-blind study, patients receiving a selective COX2 inhibitor celecoxib showed significantly reduced occurrence of colorectal adenomas within 3 years of surgical removal of colorectal adenomatous polyps [258].”
Guidelines for colorectal cancer screening and surveillance in moderate and high risk groups (update from 2002) (2010, background): “and in 5 of 1561 patients within 1 year of colonoscopy.”
The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment. (2009, background): “for colorectal cancer have cast doubt on the suitability of such drugs for long-term use, due to increased risks of adverse cardiovascular events [30,161].”
The Role of COX-2 in Intestinal Inflammation and Colorectal Cancer (2009, neutral): “, 2006), the Prevention of Colorectal Sporadic Adenomatous Polyps (PreSAP) trial (Arber et al., 2006) and the Adenomatous Polyp Prevention on Vioxx (APPROVe) trial (Bresalier et al.”
The tumour microenvironment as a target for chemoprevention (2007, neutral): “For example, recent findings indicate that although celecoxib is an effective agent for the prevention of colorectal adenomas, it cannot be routinely recommended for this indication at present because of potential cardiovascular event”